Stock listing

Dusseldorf:VIA Viatris Inc. Aktie

German listing (Dusseldorf) of Viatris Inc. · home listing NASDAQ:VTRS

Follow Viatris Inc. into a list and get an email when it puts out news.

Share price · DUS:VIA

€17.00 EUR +0.22 (+1.3%)

Close on Oct 30, 2026

Day range
€16.91 – €17.13 EUROct 30, 2026
Viatris Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:VTRS · Home$19.04 USD-0.165 (-0.9%)8,792,444$19.29$19.51$19.00$19.20Close on Oct 30, 2026
Xetra:VIA€16.69 EUR+0.564 (+3.5%)850€16.31€16.73€16.14€16.13Close on Oct 27, 2026
Frankfurt:VIA€17.29 EUR+0.794 (+4.8%)479€16.98€17.29€16.98€16.50Close on Oct 30, 2026
Dusseldorf:VIA€17.00 EUR+0.224 (+1.3%)—€16.96€17.13€16.91€16.78Close on Oct 30, 2026
Ticker
Dusseldorf:VIA
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
Dusseldorf
Currency
EUR

What changed lately

Calls

Upcoming

  • Viatris (NASDAQ:VTRS) Q3 2026 Earnings Call

    Thu, Nov 05, 2026 · 8:30 AM ET

    Register

Replays

  • Viatris (NASDAQ:VTRS) Q2 2026 Earnings Call

    Thu, Aug 06, 2026 · 8:30 AM ET

    Watch Transcript

  • Viatris (NASDAQ:VTRS) Q1 2026 Earnings Call

    Thu, May 07, 2026 · 8:30 AM ET

    Watch Transcript

  • Viatris (NASDAQ:VTRS) Q4 2025 Earnings Call

    Thu, Feb 26, 2026 · 8:30 AM ET

    Watch Transcript

Latest news

Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.

Oct 30, 2026

Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia

Oct 16, 2026

Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies

Oct 8, 2026

Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026

Oct 5, 2026

Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year

Sep 29, 2026

Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome

Sep 16, 2026

Viatris Reports Second-Quarter 2026 Financial Results

Aug 6, 2026

Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch

Jul 29, 2026

Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026

Jul 1, 2026

Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy

Jun 29, 2026

All Viatris Inc. news

Decks

Viatris Inc. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
39 in the last 12 months · 201 in all · newest Oct 30, 2026 · oldest 2020
Calls
20 calls with a replay · 20 with a transcript · latest Aug 6, 2026
Decks
56 decks · latest Aug 6, 2026

Where Viatris Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:VTRS · Home listingNASDAQUnited StatesUSD
BX Swiss:VTRSBX SwissSwitzerlandCHF
Tradegate:VIATradegateGermanyEUR
gettex:VIAgettexGermanyEUR
Xetra:VIAXetraGermanyEUR
Milan:1VTRSMilanItalyEUR
LS Exchange:A2QAMELS ExchangeGermanyEUR
Lang & Schwarz:A2QAMELang & SchwarzGermanyEUR
BMV:VTRSBMVMexicoMXN
Frankfurt:VIAFrankfurtGermanyEUR
EUROTLX:4VTRSEUROTLXItalyEUR
LSIN:0A5VLSINUnited KingdomUSD
BIVA:VTRSBIVAMexicoMXN
SIX Swiss:VTRSSIX SwissSwitzerlandCHF
Dusseldorf:VIA · This pageDusseldorfGermanyEUR
SIX Swiss:VTRS.USDSIX SwissSwitzerlandUSD
Stuttgart:VIAStuttgartGermanyEUR
BOATS:VTRSBOATSUnited StatesUSD
Hamburg:VIAHamburgGermanyEUR
Munich:VIAMunichGermanyEUR
Turquoise:VTRSNTurquoiseUnited KingdomUSD
VIE:VTRSViennaAustriaEUR
Hanover:VIAHanoverGermanyEUR

Log in to ask 6ix AI your own questions about Viatris Inc.